Inhibikase Therapeutics (IKT) News Today $1.77 -0.07 (-3.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IKT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Inhibikase Therapeutics Reports Q1 2025 Financial ResultsMay 23 at 12:12 AM | tipranks.comSoleus Capital Management L.P. Takes $20.56 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)Soleus Capital Management L.P. bought a new position in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,325,000 shares of the company's stock, valued at approximatelyMay 21, 2025 | marketbeat.comStonepine Capital Management LLC Makes New $3.68 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)Stonepine Capital Management LLC purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,132,388 shaMay 20, 2025 | marketbeat.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | finance.yahoo.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | globenewswire.comFairmount Funds Management LLC Purchases Shares of 6,125,000 Inhibikase Therapeutics, Inc. (NYSE:IKT)Fairmount Funds Management LLC acquired a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 6,125,000 shares of the company's stock, valued at apprMay 10, 2025 | marketbeat.comBlackstone Inc. Makes New Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)Blackstone Inc. purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,070,684 shares of the company's stock, valued at approximately $May 8, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 5, 2025 | prnewswire.comGeode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT)Geode Capital Management LLC grew its position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) by 544.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 322,878 shares of the company'sMay 3, 2025 | marketbeat.comInhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 2, 2025 | seekingalpha.comNantahala Capital Management LLC Makes New $7.12 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)Nantahala Capital Management LLC acquired a new position in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,190,000 shares of the company's sApril 30, 2025 | marketbeat.comInhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-marketApril 16, 2025 | nasdaq.comInhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14, 2025 | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14, 2025 | globenewswire.comADAR1 Capital Management LLC Takes $16.59 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)ADAR1 Capital Management LLC bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,103,005 shares of the company'April 9, 2025 | marketbeat.comHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Earns "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Inhibikase Therapeutics in a report on Friday.March 29, 2025 | marketbeat.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - Here's What HappenedMarch 18, 2025 | marketbeat.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comInhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deInhibikase Therapeutics appoints Mark Iwicki as CEOFebruary 18, 2025 | markets.businessinsider.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s GrowthFebruary 18, 2025 | finance.yahoo.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for IKT Q1 Earnings?Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inhibikase Therapeutics in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company willFebruary 17, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)February 13, 2025 | msn.comInhibikase Therapeutics downgraded to Neutral from Buy at H.C. WainwrightFebruary 12, 2025 | markets.businessinsider.comInhibikase Therapeutics (NYSE:IKT) Downgraded to Neutral Rating by HC WainwrightHC Wainwright lowered Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.February 12, 2025 | marketbeat.comInhibikase Halts Parkinson's Drug Development to Focus on PAHJanuary 30, 2025 | msn.comInhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in studyJanuary 29, 2025 | reuters.comInhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Should You Sell?Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Here's WhyJanuary 28, 2025 | marketbeat.comBullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of StockJanuary 21, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher - Still a Buy?Inhibikase Therapeutics (NYSE:IKT) Shares Up 3.4% - Time to Buy?December 27, 2024 | marketbeat.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Trading 7% Higher - Time to Buy?November 30, 2024 | marketbeat.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comInhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityNovember 14, 2024 | globenewswire.comJefferies Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy RecommendationNovember 9, 2024 | msn.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Financial Moves and Promising Pipeline Fuel Buy RatingOctober 24, 2024 | markets.businessinsider.comInhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Acquires 145,000 SharesOctober 24, 2024 | insidertrades.comPerceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics IncOctober 22, 2024 | finance.yahoo.com Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address IKT Media Mentions By Week IKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼1.090.77▲Average Medical News Sentiment IKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼31▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRVI News KURA News STOK News MNMD News VALN News OPT News ETON News TYRA News RLAY News RGNX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IKT Stock Free IKT Stock Alerts